Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit

Set Alert for Brexit

Parliament Tells PM To Take 'All Necessary Steps' To Keep UK In EMA After Brexit

Members of parliament in the UK want the government to take "all necessary steps" to keep the country in the EU medicines regulatory network after Brexit. It's not that easy, though.

Europe Brexit Regulation

Long-Awaited Brexit White Paper Lays Out UK’s Plans For Medicines Regulation

The UK government has finally published its white paper on the UK’s future relationship with the EU following Brexit, to the relief of the pharmaceutical industry.
Brexit Regulation Europe

Latest From Brexit

Q&A: Ireland's Success In Attracting Medtech Companies

Medtech Insight talked to Rachel Shelly, the Head of Medical Technologies for IDA Ireland, about the Irish government's continuing efforts to attract medtech companies, the implications of Brexit, and the growing emphasis on data-analytics within the medtech industry in Ireland.

Ireland Brexit

Brexit Hits Third Countries – CPPs Delayed

The European Medicines Agency is struggling to meet its 10-day turnaround for issuing certificates of pharmaceutical products (CPPs), documents that many countries outside Europe rely on to make their own regulatory decisions.

Brexit International

Submit Your Brexit-Related Changes Before We Move: EMA Plea To Industry

A continuous two-way dialogue on Brexit between the European Medicines Agency and industry is a must. The EMA is tentatively planning three Brexit-related events for stakeholders and, in the meantime, it wants companies to keep it abreast of their plans for products affected by the UK’s departure from the EU

Brexit Market Access

Unease Mounts Over Brexit Drug Shortage Risk

Not enough is known about how industry is preparing for Brexit when it comes to drugs approved via Europe’s mutual recognition and decentralized procedures. National regulators are urging companies to get their house in order.

Brexit Market Access

EMA To Discuss Reactivating Landmark Clinical Trials Transparency Policy

The European Medicines Agency will be looking at reviving its policy on proactive publishing of clinical study reports, which is currently suspended as the agency copes with huge staff losses on account of Brexit.
 
Europe Brexit

No-Deal Brexit Means ‘Re-Planning A Whole Industry,’ Says ABPI Chief

Mike Thompson, head of the Association of the British Pharmaceutical Industry, outlined his industry’s concerns over medicines stockpiling, batch testing, tariffs, regulatory collaboration and other issues at a parliamentary committee hearing on the implications of a no-deal Brexit.

Brexit Europe

QUOTED. Oct. 11, 2018. Jonathan Mogford.

Negotations over the UK's impending exit from the EU are heating up, but there is not enough focus on what needs to happen to get to a mutually beneficial agreement between the two parties, says a top official at the UK agency that regulates devices and. See part of what Jonathan Mogford had to say here.

Brexit Quoted

Brexit: We Really Are Worth Keeping, Says Senior UK Regulator

Not enough is being said about how to get a positive outcome from Brexit and those interested in seeing a continued close regulatory partnership between the UK and the EU should make their voice heard, says Jonathan Mogford, policy director at the Medicines and Healthcare products Regulatory Agency.

Brexit Policy & Regulation

Brexit: We Really Are Worth Keeping, Says Senior UK Regulator

Not enough is being said about how to get a positive outcome from Brexit and those interested in seeing a continued close regulatory partnership between the UK and the EU should make their voice heard, says Jonathan Mogford, policy director at the Medicines and Healthcare products Regulatory Agency.

Brexit Regulation
See All
Advertisement
UsernamePublicRestriction

Register